ACCORD HEALTHCARE LIMITED
Location
Founded
2004-04-13
Risk Signals
337 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ACCORD HEALTHCARE LIMITED
Live alerts from global media, monitored by Business Radar
2021-07-07 (pharmaceutical-journal.com)
NHS trusts forced to use ‘expensive’ pre-filled diamorphine syringes to manage ongoing supply issues
Demand has increased for “expensive” pre-filled syringes of diamorphine hydrochloride, as 5mg and 10mg ampoule products continue to face supply issues, hospital pharmacists have said. Diamorphine hydrochloride, an opioid used to manage severe pain, first faced supply problems in February 2020, when
Read more
2021-05-20 (cleanroomtechnology.com)
A guide to choosing cleanroom flooring
David Priest from Kemtile gives a rundown of the key considerations when selecting a resin floor for cleanrooms and controlled environments
Read more
2021-02-12 (pharmaceutical-journal.com)
Manufacturer to move hydroxychloroquine production to the UK to avoid shortages - The Pharmaceutical Journal
A manufacturer has announced plans to move production of hydroxychloroquine — currently being trialled as a COVID-19 treatment — to the UK from abroad to combat potential shortages.
Read more
2020-05-19 (outsourcing-pharma.com)
Sterling Pharma kicks off hydroxychloroquine production
The British CDMO will manufacture the API for the potential COVID-19 treatment, and partner Accord Healthcare will manufacture the finished product.
Read more
2020-05-05 (pharmaceutical-journal.com)
Manufacturer to move hydroxychloroquine production to the UK to avoid shortages
A manufacturer has announced plans to move production of hydroxychloroquine — currently being trialled as a COVID-19 treatment — to the UK from abroad to combat potential shortages.
Read more
2019-10-10 (pharmaphorum.com)
A new breed of pharma manufacturing -
Over the last few years the effect of Brexit’s political instability on our industry has been inescapable as generic and branded manufacturers alike prepare for its impact on medicine production supply chains
Read more